Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol
Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
In hemodialysed patients, coronary heart disease is the leading cause of mortality and
morbidity. Most of the commonly used drug for ischemia are used in this patients, but few
prospective data are available. Among anti-ischemic drugs betablocker provided evidence of
beneficial effects on outcome and, in dialysis patients, carvedilol was successfully used
also in heart failure. Ivabradine is the latest anti-ischemic drug that provided evidence of
benefit in general population, but no study is available in dialysis patients. Aim of the
present study is to compare in a randomized, double-blind, parallel group trial the effects
of ivabradine compared with carvedilol on event-free survival at 18 months in a hemodialysed
population of patients with established coronary heart disease.
Phase:
Phase 4
Details
Lead Sponsor:
Second University of Naples University of Campania "Luigi Vanvitelli"